Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

How Ozempic Is Forcing Fashion to Rethink Fit

It’s not just about ordering more smalls. Brands must grapple with growing ‘size volatility’ as more consumers use GLP-1 drugs.
The Ozempic era is forcing fashion to rethink not just sizing, but how garments are designed, allocated and sold.
The Ozempic era is forcing fashion to rethink not just sizing, but how garments are designed, allocated and sold. (Shutterstock)

Key insights

  • GLP-1-driven weight loss is exposing long-standing flaws in fashion’s sizing, fit and inventory planning systems.
  • The best-positioned brands are increasingly designing for body fluctuation and “size volatility,” rather than treating sizing as fixed and static.
  • Retailers that can offer flexibility, speed and personalised fit solutions may gain an advantage as GLP-1 users emerge as a powerful new consumer cohort.

Further Reading

About the author
Sheena Butler-Young
Sheena Butler-Young

Sheena Butler-Young is Senior Correspondent at The Business of Fashion. She is based in New York and covers workplace, talent and issues surrounding diversity and inclusion.

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

Recommended For You

Loading recommended reads…

Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.

Breakout Model Jacqui Hooper on Reading the Room

Hooper talks to Imran Amed on The BoF Podcast about what it really takes to make it as a model today, the growing expectation that models double as content creators, and why she’d rather not “sing about it on Instagram.”

VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON
Voices 2026 - Global Livestream, December 1-3